Researchers are increasingly investigating retatrutide, a novel drug from Eli Lilly, as a potential advance in physique loss . Distinct from many previous approaches, retatrutide is a double -action receptor targeting simultaneously GLP-1 and GIP, substances that affect hunger and blood glucose c… Read More